Rethinking (drug) design

The RETHINK initiative of ETH Zurich brings together experts from industry and academia to exploit the potential of artificial intelligence for design processes. ETH Prof. Gisbert Schneider and Dr. Matthias Zentgraf (Boehringer Ingelheim Pharma) explain the benefits for drug design.

By playing the video you accept the privacy policy of YouTube.Learn more OK
Video: ETH Zurich

Contact / Links:

Prof. Gisbert Schneider, RETHINK

Do you want to get more "News for Industry" stories?

external pageSubscribe to our newsletter

external pageFollow us on LinkedIn

Are you looking for research partners at ETH Zurich?

Contact ETH Industry Relations

 

 

JavaScript has been disabled in your browser